newsfilter
← Latest News
Business Wire·

ODDITY Launches METHODIQ, a Telehealth Platform Reimagining Medical Care

ODD
  • ODDITY Tech Ltd. (NASDAQ: ODD) announced the launch of METHODIQ, a medical telehealth platform delivering customized, high-efficacy treatments via online diagnosis without requiring in-person visits.
  • The platform initially focuses on dermatology conditions affecting approximately 110 million Americans, including acne, hyperpigmentation, and eczema, with plans to expand into other medical domains.
  • METHODIQ integrates AI-powered skin analysis, computer vision-based progress tracking, and a portfolio of 28 core products offering over 100 personalized treatment plans.
  • The product suite includes prescription, OTC, and cosmetic formulations, featuring ingredients discovered by ODDITY Labs' biotech lab in Boston, MA.
  • Proprietary vision technology was trained on more than 1 million images of real individuals to quantify skin markers and track progress through weekly check-ins in the METHODIQ App.
  • Oran Holtzman, co-founder and CEO of ODDITY, stated the launch aims to serve the company's existing base of over 60 million users by addressing dissatisfaction with current solutions.
  • Tom Amsterdam, CEO of METHODIQ, emphasized that the platform was designed with board-certified dermatologists to rebuild healthcare delivery with less friction and higher efficacy.
  • ODDITY operates with headquarters in New York City, an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston, owning brands such as IL MAKIAGE, SpoiledChild, and METHODIQ.
  • The press release includes standard forward-looking statements regarding future growth, market opportunities, and potential risks associated with the new platform launch.